Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...
The companies anticipate finalising the acquisition in the third quarter of 2026.
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results